Abstract:With identical major and minor human leukocyte antigen, how did GVHD develop in patients undergoing syngeneic- or auto-HCT? Glazier et al. [4] initially demonstrated in animal transplant models that the phenomenon indistinguishable from classic acute GVHD could develop in CsA-treated and lethally irradiated rats after syngeneic or autologous BM reconstitution. These findings were later confirmed by other researchers and subsequent studies using preclinical models and human samples from CsA-induced auto GVHD. These highlight the following key points; (1) autoreactive CD8 + T cell clones that recognize MHC class II determinants in association with Class II-associated invariant chain peptide (CLIP) molecules are responsible for the development of auto-GVHD, (2) regulatory T cells (Tregs) act as a counterpart to these CD8 + T cells and prevents auto-GVHD, (3) thymus has an essential role in generating both autoreactive and immunoregulatory T cells, (4) CsA treatment (potentially other calcineurin inhibitors) hampers the central tolerance process, wherein potentially autoreactive T cells are eliminated in the thymus. What can be said about these findings in CsA-induced auto-GVHD animal models as they pertain to spontaneous auto-GVHD cases? While instructive, it must be admitted that the mechanisms and factors driving CsA-induced auto-GVHD and spontaneous auto-GVHD remain to be completely elucidated. While thymopoiesis and central tolerance may play a fundamental role in mouse models of CsA-induced auto-GVHD, thymopoiesis does not contribute considerably to T cell reconstitution until at least 6 months post-transplant in patients [5]. Onset of auto-GVHD predominantly occurs within 2–3 weeks of transplant where thymic-independent peripheral expansion of infused T cells is likely to play the major role in immune reconstitution [6]. The origin of autoreactive CD8 + T cells against self-MHC II antigen are thus more likely to arise from break of peripheral tolerance than central tolerance. Although self-reactive T cells are deleted in the thymus through negative selection and are expected to be absent in the periphery, some can nevertheless be found in the blood. In this situation, break of peripheral tolerance leads to the expansion of autoreactive CD8 + T cells driven by self-antigens and cytokines elaborated from injured tissues, as well as innate immune activation incurred by preparative conditioning procedure. Indeed, it is likely that impairment in function and delayed reconstitution of Tregs, influenced by pre-treatment chemotherapy and host susceptibility factors is at the heart of spontaneous auto-GVHD pathology. In the context of peripheral tolerance, programmed death (PD) 1 and programmed death-ligand 1 (PD-L1) pathway may also contribute to drive autoinflammation in auto-GVHD. PD-1 −/ − phenotype mice develop a lupus-like glomerulonephritis and destructive arthritis, accompanied by the activation of potentially autoreactive T cells in vivo [7]. Beyond its influence on the effector T cells, PD-1 ligation increases the generation of induced T regs from naïve CD4 + T cells and enhances their suppressive function, ultimately enabling the restraint of pathogenic T cells that have escaped into the periphery [8]. In a murine allogeneic transplant model [9], while both ileum and heart had a similar repertoire of infiltrating T cells, the ileum was only susceptible to T-cell-mediated tissue destruction, whereas the heart was not. PD-L1 expression was significantly elevated in heart tissue but almost absent in the ileum. These findings suggest that the PD1-PD-L1 pathway may involve organ-specific peripheral tolerance mechanisms and play a role in either facilitating or protecting against T-cell-mediated tissue damage responsible for GVHD. Currently, a series of publications report that prior PD-1 blockade possibly alters the post-HCT course by amplifying the graft-versus-tumor effect while increasing the risk of GVHD [10]. Although most clinical reports on this topic are derived from allo-HCT settings, taken together, it is tempting to speculate that the previous exposure to anti-PD-1 treatment in our second case may have contributed to their susceptibility to developing auto-GVHD. In addition, the relatively high occurrence of auto-GVHD in the peri-engraftment period raises the possibility of a connection with engraftment syndrome. Moreover, engraftment syndrome and auto-GVHD have similar clinical manifestations and exhibit indistinguishable skin biopsy pathological findings. As Cornell et al. have suggested [11], auto-GVHD may fall on a spectrum with engraftment syndrome as an autoinflammatory consequence of breakdown in self-tolerance after auto-HCT.

Clinical and Treatment History of Patients with Partial DiGeorge Syndrome and Autoimmune Cytopenia at Multiple Centers

DiGeorge syndrome complicated with hyperthyroidism: one case report and literature review

[Autoimmune Disorder Secondary to DiGeorge Syndrome: a Long-Term Follow-Up Case Report and Literature Review].

Chromosome 22q11.2 Deletion (DiGeorge Syndrome): Immunologic Features, Diagnosis, and Management

Autoimmune Cytopenias and Associated Conditions in CVID: a Report From the USIDNET Registry

Daratumumab therapy for post-HSCT immune-mediated cytopenia: experiences from two pediatric cases and review of literature

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Role of Immunotherapy in Down Syndrome Disintegrative Disorder (DSDD)

Immunotherapy in selected patients with Down syndrome disintegrative disorder

Clinical characteristics and outcomes of pediatric patients with autoimmune gastritis

Psychopharmacological management in patients with Di George syndrome

Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients

Case Report: Nontuberculous mycobacterial infections in children with complete DiGeorge anomaly

Hypoparathyroidism Associated with Benign Thyroid Nodules in DiGeorge-like Syndrome: A Rare Case Report and Literature Review

Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study

Autoimmunity as a continuum in primary immunodeficiency

Case Report: Improvement Following Immunotherapy in an Individual With Seronegative Down Syndrome Disintegrative Disorder

Characterizing Autoimmune Hemolytic Anemia in RAG Deficiency

Immunological Insights from a Multicenter Study

GVHD like skin eruption post-autologous stem cell transplantation

Treatment and response of autoimmune cytopenia occurring after allogeneic hematopoietic cell transplantation in children